During the last session, FibroGen Inc (NASDAQ:FGEN)’s traded shares were 1.29 million, with the beta value of the company hitting 0.74. The 52-week high for the FGEN share is $2.93, that puts it down -737.14 from that peak though still a striking 48.57% gain since the share price plummeted to a 52-week low of $0.18. The company’s market capitalization is $35.27M, and the average intraday trading volume over the past 10 days was 1.8 million shares, and the average trade volume was 1.22 million shares over the past three months.
FibroGen Inc (FGEN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 4.00. FGEN has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FibroGen Inc (NASDAQ:FGEN) trade information
The stock’s 5-day price performance is 5.36%, and it has moved by -0.09% in 30 days. Based on these gigs, the overall price performance for the year is -33.85%. The short interest in FibroGen Inc (NASDAQ:FGEN) is 4.32 million shares and it means that shorts have 3.27 day(s) to cover.
The consensus price target of analysts on Wall Street is $28, which implies an increase of 98.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $28 and $28 respectively. As a result, FGEN is trading at a discount of -7900.0% off the target high and -7900.0% off the low.
FibroGen Inc (FGEN) estimates and forecasts
Statistics show that FibroGen Inc has outperformed its competitors in share price, compared to the industry in which it operates. FibroGen Inc (FGEN) shares have gone down -71.54% during the last six months, with a year-to-date growth rate more than the industry average at 67.79% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 64.91% this quarter and then jump 69.70% in the quarter after that. In the rating firms’ projections, revenue will increase 17.20% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 24M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 39.43M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 27.14M and 55.9M respectively. In this case, analysts expect current quarter sales to shrink by -11.56% and then drop by -29.47% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.23%. While earnings are projected to return 69.86% in 2024.
FGEN Dividends
FibroGen Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
FibroGen Inc (NASDAQ:FGEN)’s Major holders
FibroGen Inc insiders own 0.85% of total outstanding shares while institutional holders control 55.04%, with the float percentage being 55.51%. PRIMECAP MANAGEMENT CO/CA/ is the largest shareholder of the company, while 115.0 institutions own stock in it. As of 2024-06-30, the company held over 13.66 million shares (or 13.7964% of all shares), a total value of $12.19 million in shares.
The next largest institutional holding, with 8.94 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 9.0279% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $7.97 million.
